Oral candidiasis in HIV+ patients under treatment with protease inhibitors

Brazilian Oral Research

Volumn 22, Issue 4, 2008, Pages 371-377

  Witzel, Andréa Lusvarghi ^a,d   da Silveira, Fernando Ricardo Xavier ^a   Pires, Maria de Fátima Costa ^b   Lotufo, Mônica Andrade ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

^c IBIRAPUERA UNIVERSITY   (Brazil)

^d NONE   (Brazil)

Author keywords

Candida albicans; HIV; Protease inhibitors

Indexed keywords

EID: 60649107361     PISSN: 18068324     EISSN: 18073107     Source Type: Journal    
DOI: 10.1590/S1806-83242008000400015     Document Type: Article

References (28)

1. Odds FC. Candida and candidosis. 2nd ed. London, Baillière Tindal; 1988. 468 p.
2. Sullivan D, Coleman D. Candida dubliniensis: characteristics and identification. J Clin Microbiol. 1998 Feb;36(2):329-34.
3. Diz Dios P, Ocampo A, Otero I, Iglesias I, Martínez C. Changes in oropharyngeal colonization and infection by Candida albicans in human immunodeficiency virus-infected patients. J Infect Dis. 2001 Jan 15;183(2):355-6.
4. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981 Dec 10;305(24):1425-31.
5. Korting HC, Ollert M, Georgii A, Fröschl M. In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol. 1988 Dec;26(12):2626-31.
6. Torssander J, Morfeldt-Månson L, Biberfeld G, Karlsson A, Putkonen PO, Wasserman J. Oral Candida albicans in HIV infection. Scand J Infect Dis. 1987;19(3):291-5.
7. Hadley S, Martinez JA, McDermott L, Rapino B, Snydman DR. Real time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients. J Antimicrob Chemother. 2002 Feb;49(2):415-9.
8. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med. 1996 Jun 20;334(25):1674-5.
9. Vargas KG, Joly S. Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals. J Clin Microbiol. 2002 Feb;40(2):341-50.
10. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis. 1999 Aug;180(2):448-53.
11. Murphy M, Armstrong D, Sepkowitz KA, Ahkami RN, Myskowski PL. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS. 1997 Feb;11(2):261-2.
12. Grube H, Ramratnam B, Ley C, Flanigan TP. Resolution of AIDS-associated cryptosporidiosis after treatment with indinavir. Am J Gastroenterol. 1997 Apr;92(4):726.
13. Hood S, Bonington A, Evans J, Denning D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS. 1998 Mar 5;12(4):447-8.
14. Valdez H, Gripshover BM, Salata RA, Lederman MM. Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy. AIDS. 1998 Mar 26;12(5):538.
15. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA. 1997 Jan 8;277(2):145-53.
16. Gruber A, Speth C, Lukasser-Vogl E, Zangerle R, Borg-von Zepelin M, Dierich MP et al. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology. 1999 Apr;41(3):227-34.
17. Schmid J, Odds FC, Wiselka MJ, Nicholson KG, Soll DR. Genetic similarity and maintenance of Candida albicans strains in a group of AIDS patients demonstrated by DNA fingerprinting. J Clin Microbiol. 1992 Apr;30(4):935-41.
18. Georgopapadakou NH, Walsh TJ. Human mycoses: drugs and targets for emerging pathogens. Science. 1994 Apr 15;264(5157):371-3.
19. Samaranayake LP, Holmstrup P. Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med. 1989 Dec;18(10):554-64.
20. De Bernardis F, Chiani P, Ciccozzi M, Pellegrini G, Ceddia T, D'Offizzi G et al. Elevated Aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect Immun. 1996 Feb;64(2):466-71.
21. Wu T, Samaranayake LP, Cao BY, Wang J. In vitro proteinase production by oral Candida albicans isolates from individuals with and without HIV infection and its attenuation by antimycotic agents. J Med Microbiol. 1996 Apr;44(4):311-6.
22. Aguirre JM, Echebarria MA, Ocina E, Ribacoba L, Montejo M. Reduction of HIV-associated oral lesions after highly active antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):114-5.
23. Margiotta V, Campisi G, Mancuso S, Accurso V, Abbadessa V. HIV infection: oral lesions, Cd4+ cell count and viral load in an Italian study population. J Oral Pathol Med. 1999 Apr;28(4):173-7.
24. Ceballos-Salobreña A, Aguirre-Urizar JM, Bagan-Sebastian JV. Oral manifestations associated with human immunodeficiency virus in a Spanish population. J Oral Pathol Med. 1996 Nov;25(10):523-6.
25. Cassone A, Tacconelli E, De Bernardis F, Tumbarello M, Torosantucci A, Chiani P et al. Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. J Infect Dis. 2002 Jan 15;185(2):188-95.
26. Korting HC, Schaller M, Eder G, Hamm G, Böhmer U, Hube B. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother. 1999 Aug;43(8):2038-42.
27. Hoegl L, Thoma-Greber E, Röcken M, Korting HC. Shift from persistent oral pseudomembranous to erythematous candidosis in a human immunodeficiency virus (HIV)-infected patient upon combination treatment with an HIV protease inhibitor. Mycoses. 1998 May-Jun;41(5-6):213-7.
28. Conant MA, Opp KM, Poretz D, Mills RG. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir. AIDS. 1997 Aug;11(10):1300-1.